Home›Clinical trials›Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

A study listed on ClinicalTrials.gov.

Recruiting now. Registry record last updated December 31, 2025.

Who can join
Adults 30 to 65.
What you take
Check ClinicalTrials.gov for this trial's study groups and what each group receives.
How long it lasts
The study runs about 4 months.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Not ApplicableSponsor Cytrellis Biosystems, Inc.Drug investigational drugClass OtherSites 1 USEnrollment target 10

What this study is for

Primary condition: glp1 Agonist. Also studied in: Gene Expression, Skin Laxity.

Full scientific study title: Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists.

Who can join

Age30 to 65SexAny

Adults 30 to 65. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Male and female adult, between the ages of 30 and 65
  • Fitzpatrick Skin Type I-VI
  • Have moderate to severe wrinkles on the mid and lower face, according to Lemperle Wrinkle Severity Scale (LWSS), i.e. score 3, 4 or 5.
  • Have moderate to extreme abdominal laxity according to Stokes Scale (i.e., score of 2-4 on a scale of 0-4).
  • Willingness to sign Informed Consent Form

Key exclusion criteria

  • Pregnant women or nursing mothers
  • Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area
  • Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine
  • Patients with a history or presence of any clinically significant bleeding disorder
  • Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules/nodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

California1 site

Timeline

Started enrolling: October 14, 2025. Expected completion: February 28, 2026. Last updated on ClinicalTrials.gov: December 31, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.